Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse for negative symptoms in schizophrenia
NCT01760993Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2013
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in schizophrenia, sponsored by Takeda. Started Feb 2013; status: terminated.
02
Drugs
lisdexamfetamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01760993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01760993.